6.560USDMkt Cap: 254.66M USDP/E: —Last update: 2026-05-22
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considere…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap254.66M USD
Enterprise Value22.26M USD
Revenue (TTM)5.74M USD
Gross Profit-135.81M USD
Net Income (TTM)-143.75M USD
Revenue/Share0.1380 USD
Last Price6.560 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees152
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.85
PEG—
EV/EBITDA-0.13
EV/Revenue3.88
P/S42.69
P/B0.74
EPS (TTM)-4.00
EPS (Forward)-3.41
52W Range
6.44037% of range6.760
52W High6.760 USD
52W Low6.440 USD
Profitability
Gross Margin0.00%
Oper. Margin-4834.63%
EBITDA Margin0.00%
Profit Margin-565.48%
ROE-46.96%
ROA-38.09%
Growth
Revenue Growth-95.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-128.51M USD
CapEx (TTM)1.04M USD
FCF Margin-1313.72%
FCF Yield-29.60%
Net Debt-205.11M USD
Net Debt/EBITDA1.19
Balance Sheet
Debt/Equity0.17
Current Ratio13.90
Quick Ratio13.40
Book Value/Sh8.504 USD
Cash/Share7.073 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)19.50 USD
Target Range10.00 USD – 25.00 USD
# Analysts4
Ownership
Shares Out.38.82M
Float21.39M
Insiders12.31%
Institutions78.42%
Short Interest
Short Ratio5.6d
Short % Float4.00%
Short % Out.2.57%
Shares Short998.35K
Short (prev mo.)894.15K
Technical
SMA 5011.74 (-44.1%)
SMA 2009.334 (-29.7%)
Beta-0.09
S&P 52W Chg28.31%
Avg Vol (30d)366.39K
Avg Vol (10d)675.53K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—